Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: A retrospective cohort study Journal Article
| Authors: | Chan, J. S. K.; Lee, Y. H. A.; Leung, C. H.; Leung, D. K. W.; Dee, E. C.; Ng, K.; Tse, G.; Ng, C. F. |
| Article Title: | Associations between glucocorticoid use and major adverse cardiovascular events in patients with prostate cancer receiving antiandrogen: A retrospective cohort study |
| Abstract: | BackgroundPrednisolone/prednisone coadministration with abiraterone may explain abiraterone-related increase in cardiovascular risk. We explored this postulation and glucocorticoid's association with cardiovascular risk.MethodsPatients with prostate cancer on androgen deprivation therapy and enzalutamide, or abiraterone with 5 mg (ABI + P5) or 10 mg (ABI + P10) daily total prednisolone/prednisone were followed up for major adverse cardiovascular events (MACE).ResultsWe analyzed 933 patients. ABI + P10, but not enzalutamide, had higher risk of MACE than ABI + P5. Cumulative glucocorticoid dose before enzalutamide/abiraterone initiation was associated with MACE.ConclusionsPrednisolone/prednisone coadministration with abiraterone likely contributed to abiraterone-related increased cardiovascular risk. Prevalent cumulative glucocorticoid dose was associated with cardiovascular risk. |
| Journal Title: | Prostate Cancer and Prostatic Diseases |
| Volume: | 28 |
| Issue: | 2 |
| ISSN: | 1365-7852 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2025-06-01 |
| Start Page: | 516 |
| End Page: | 518 |
| Language: | English |
| ACCESSION: | WOS:001309230700001 |
| DOI: | 10.1038/s41391-024-00889-x |
| PROVIDER: | wos |
| PMCID: | PMC12106070 |
| PUBMED: | 39256550 |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF -- Source: Wos |
